•  View Shopping Cart | 
•  STAR Account

Overview

Your monoclonal antibody production yield is only as good as the cells used for production. Before beginning production, your hybridoma cell line is examined in three stages. This process identifies and corrects problem cell lines before production begins.

RECOVERY: We determine the viability of the cells in the cryovial you supply to us. If the culture viability is acceptable at thaw, recovery work is not required and we move to Clonality determination. If the viability of the cells at thaw is poor, SDI attempts to recover viable cells and establish a thriving, viable culture.

CLONALITY: After establishing a viable culture, the clonality of the culture is determined. In this process, the fraction of cells in the culture secreting antibody is determined. Only hybridoma cell lines with good clonality (a large fraction of the cells in the culture secreting antibody) are used for monoclonal antibody production.

SUBCLONING: When the clonality of the culture is unacceptable (the fraction of cells in the culture secreting antibody is low), SDI subclones the original culture by selecting the best antibody-secreting clone and establishing a new culture. This new culture is used for monoclonal antibody production.

This process allows only strong hybridoma cell cultures to be used for antibody production work, greatly reducing the likelihood producing an unexpectedly low amount of monoclonal antibody.

Monoclonal antibody is produced using in vivo (ascites) and in vitro (roller bottle) methods. All processes following current Good Manufacturing Practices (cGMP). Hybridoma cell lines to be used for repeated monoclonal antibody production are frozen in Cell Banks. Master Cell Banks and Manufacturer's Working Cell Banks provide a stable uniform starting point for predictable monoclonal antibody production.

Complete and fax the Custom Monoclonal Project Submission form, then send us the signed original with your antigen.

Full ordering instructions here.